A Relative Strength Rating upgrade for Alkermes shows improving technical performance. Will it continue?

Alkermes recently highlighted new data from its Vibrance-1 phase 2 study of alixorexton in narcolepsy type 1, showing clinically meaningful improvements in wakefulness, cognition and fatigue over 13 ...

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, May 5, 2026 to discuss the company’s first quarter financial results.

View Alkermes Public Limited Company ALKS stock quote prices, financial information, real-time forecasts, and company news from CNN.

Investors in Alkermes plc ALKS need to pay close attention to the stock based on moves in the options market lately. That is because the May 15, 2026 $50.00 Call had some of the highest implied ...

Alkermes (NASDAQ:ALKS) is gearing up to announce its quarterly earnings on Thursday, 2024-10-24. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

(Reuters) -Alkermes said on Wednesday it will acquire Avadel Pharmaceuticals in a deal valued at up to $2.1 billion, gaining an approved sleep-disorder treatment and expanding into the sleep medicine ...

DUBLIN, Sept. 11, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Monday, Sept.

Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its inaugural Alkermes Pathways APN Research Awards™ program on Monday, March 16, 2026. This competitive grant ...